



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/622,407-Conf. #2359
				Filing Date	July 17, 2003
				First Named Inventor	Chris Saris
				Art Unit	1646
				Examiner Name	Eileen O'Hara
Sheet	1	of	2	Attorney Docket Number	01017/35434B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
EOH	A1	US-5,489,743	02/1996	Robinson et al.	
	A2	US-5,843,789	12/1998	Nomura et al.	
	A3	US-5,863,769	01/1999	Young	
↓	A4	US-5,942,385	08/1999	Hirth	
↓	A5	US-6,346,382	02/2002	Summar et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
EOH	B1	DE-19809978	09/1999		
	B2	EP-0861850	09/1998		
	B3	WO-96/14328	05/1996		
	B4	WO-96/37609	11/1996		
	B5	WO-98/30694	07/1998		
	B6	WO-9843998	10/1998		
	B7	WO-99/04001	01/1999		
	B8	WO-99/06426	02/1999		
	B9	WO-99/07738	02/1999		
	B10	WO-99/14330	03/1999		
	B11	WO-99/20758	05/1999		
	B12	WO-99/23105	05/1999		
	B13	WO-99/26977	06/1999		
	B14	WO-99/35268	07/1999		
	B15	WO-99/50413	10/1999		
	B16	WO-99/51744	10/1999		
↓	B17	WO-00/08139	02/2000		
↓	B18	WO-00/18800	04/2000		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
EOH	C1	Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, pp. 34-39, 2000.			
EOH	C2	EST Database Accession No. A1747041, Jun. 22, 1999.			
EOH	C3	Locksley et al., The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology, Cell, 104:487-501(2001).			

Examiner Signature	/Eileen O'Hara/	Date Considered	06/02/2006
--------------------	-----------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/622,407-Conf. #2359
				Filing Date	July 17, 2003
				First Named Inventor	Chris Saris
				Art Unit	1646
				Examiner Name	Eileen O'Hara
Sheet	2	of	2	Attorney Docket Number	01017/35434B

EOH	C4	Moult, The Current State of the Art In Protein Structure Prediction, Curr. Op. in Biotech., 7(4):422-427(1996).
	C5	Nophar et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor, EMBOJ., 9(10):3269-3278(1990).
	C6	Orlinick and Chao, TNF-Related Ligands and Their Receptors, Cell Signal, 10(8):543-551(1998).
	C7	Ouchterlony and Nilsson, Immunodiffusion and Immunoelectrophoresis in: Handbook of Experimental Immunology ed. D. Weir, Blackwell, 1973.
	C8	Porteu et al., Human Neutrophil Elastase Releases a Ligand-binding Fragment from the 75-kDa Tumor Necrosis Factor (TNF) Receptor, J. Biol. Chem., 266:18846-18853(1991).
	C9	Smith et al., Four New Members Expand the Interleukin-1 Superfamily, J. Bio. Chem., 275(2):1169-1175(2000).
	C10	Vaitukaitis et al., A Method For Producing Specific Antisera With Small Doses of Immunogen, J. Clin. Endocrinol., 33:988-991(1971).
	C11	Wallach et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Agents Actions Suppl., 35:51-57(1991).
	C12	Baker and Reddy, Transducers of Life and Death: TNF Receptor Superfamily and Associated Proteins, Oncogene, 12(1):1-9(1996).
	C13	Beyaert and Fiers, Tumor Necrosis Factor and Lymphokines in: Cytokines eds. Anthony Mire-Sluis and Robin Thorpe, Academic Press San Diego CA, 1998.
	C14	Browning et al., Lymphotoxin .beta., a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface, Cell, 72:847-856, (1993).
	C15	Fernandez-Botran, Soluble Cytokine Receptors: Their Role In Immunoregulation, FASB J., 5:2567-2574(1991).
	C16	Fisher, Production of Antibody in Radioimmunoassay In; Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C., 1980.
	C17	Genbank accension No. aa155701, "z070e05.r1 Stratagene pancreas (#937208() Homo sapiens cDNA clone IMAGE:592256 5', mRNA sequence", Hillier et al., 1997.
	C18	Genbank accension No.: AAC50332, TNF-related Apoptosis Inducing Ligand Trail, Wiley et al., Jan. 6, 1996.
	C19	Genbank accension No.: NP033451, TNF-Related Apoptosis Inducing Ligand [Mus musculus], Wiley et al., 2000.
	C20	Genbank accension No.: CAA26669, TNF-alpha [Homo sapiens], Nedwin et al., Feb. 17, 1997.
	C21	Genbank accension No.: CAA68530, TNF-alpha [Mus musculus], Jongeneel, May 11, 1993.
	C22	Aderka et al., The Potential Biological and Chemical Significance of the Soluble Tumor Necrosis Factor Receptors, Cytokine & Growth Factor Reviews, 7(3):231-240(1996).
	C23	Aggarwal et al., Characterization of Receptors for Tumor Necrosis Factor and their Regulation By .gamma.-Interferon, Nature, 318:665-667(1985).
↓	C24	Ausubel et al., eds., Current Protocols in Molecular Biology, 1, Section 9.1.1-9.1.3, John Wiley & Sons, New York 1996.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Eileen O'Hara/	Date Considered	06/02/2006
--------------------	-----------------	-----------------	------------

Form PTO-1449 (Modified)

JUL 16 2004

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.
01017/35434BSerial No.
10/622,407Applicant(s)
Chris SarisFiling Date
July 17, 2003Art Unit
1645

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name
EOH	5,605,690	02-25-1997	Jacobs
	5,885,800	03-01-1999	Emery et al.
	5,312,733	05-01-1994	MacLeod
	6,274,339	08-01-2001	Moore et al.
	6,271,366	08-01-2001	Kimura et al.
	2003/0096355	05-22-2003	Zhang
↓	6,599,716	07-29-2003	Hsu
	2003/0082736	05-01-2003	Smith

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country
EOH	93/19777	10-14-1993	World Intellectual Property Organization (WIPO)
	94/06476	03-31-1994	World Intellectual Property Organization (WIPO)
	0 648 783	04-19-1995	European Patent Office
	98/35986	07-01-1998	World Intellectual Property Organization (WIPO)
	98/43998	10-01-1998	World Intellectual Property Organization (WIPO)
↓	99/03992	01-28-1999	World Intellectual Property Organization (WIPO)

OTHER DOCUMENTS

EOH	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family", The Rockefeller University Press, Volume 186,
EOH	Pan et al., "TRUDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Letters 424, January 12, 1998, pp. 41-45.

EXAMINER:

/Eileen O'Hara/

DATE CONSIDERED:

06/02/2006

Form PTO-1449 (Modified)		Atty. Docket No. 01017/35434B	Serial No. 10/622,407
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Chris Saris	
		Filing Date July 17, 2003	Art Unit 1645

EOH	Delgli-Esposti, "To die or not to die-the quest of the TRAIL receptors", <i>Journal of Leukocyte Biology</i> , Volume 65, May 1999, pp. 535-542.
	Schneider et al., "Characterization of two receptors for TRAIL", <i>FEBS Letters</i> 416, September 24, 1997, pp. 329-334.
	McFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL", <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 41, July
	Meurs et al., "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, January 1993, pp. 232-
	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL", <i>The EMBO Journal</i> , Vol. 16, No. 17, 1997, pp. 5386-5397.
	"KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene", <i>Nature Genetics</i> , Vol. 17, October 1997, pp. 141-143.
	Degli-Esposti, et al., "The Novel Receptor TRAIL-R4 Induces NF-kb and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain", <i>Immunity</i> , Vol.
	Naismith et al., "Modularity in the TNF-receptor family", <i>TIBS</i> 23, February 1998, pp. 74-79.
	Hofmann, "The modular nature of apoptotic signaling proteins", <i>CMLS</i> , Vol. 55, 1999, pp.1113-1128.
	Marsters, et al., "A novel receptor for ApoL/TRAIL contains a truncated death domain", <i>Current Biology</i> , Vol. 7, No. 12, 1997, pp. 1003-1006.
	Pitti, et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer", <i>Nature</i> , Vol. 396, December 17, 1998, pp. 699-703.
	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors", <i>Science</i> , Vol 277, August 8, 1997, pp. 818-821.
	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", <i>Cell</i> , Vol. 89, April 18, 1997, pp. 309-319.
	Griffith et al., "TRAIL: a molecule with multiple receptors and control mechanisms", pp. 559-563.
	Emery et al., "Osteoprotegerin is a Receptor for the Cytotoxic Ligand TRAIL", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 23, June 5, 1998, pp. 1463-1467.
	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL", <i>Science</i> , Vol. 276, April 4, 1997, pp. 111-113.
	Pan et al., "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL", <i>Science</i> , Vol. 277, August 8, 1997, pp. 815-818.
	Bucay et al., "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", <i>Genes & Development</i> , Vol. 12, 1998, pp. 1260-1268.
	Wu et al., "Molecular Cloning and Functional Analysis of the Mouse Homologue of the KILLER/DR5 Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death
	Griffith, et al., "Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL", Vol. 189, No. 8, April 19, 1999, pp. 1343-1353.
▼	Griffith, et al., "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies", <i>The Journal of Immunology</i> , 1999, pp. 2597-2605.

EXAMINER:	/Eileen O'Hara/	DATE CONSIDERED:	06/02/2006
-----------	-----------------	------------------	------------